Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WINHYPO 2021
2024-512642-42-00Phase 3Authorised
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of levothyroxine sodium in hypothyroidism (2 arms), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Hypothyroidism-free survival at 3 years. Planned start Dec 2021; status: authorised.
02
Drugs
levothyroxine sodium
03
Conditions
hypothyroidism
Beyond the preview
Go deeper on 2024-512642-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512642-42-00.